How Nicole Junkermann Decides Which Technology to Back

Start with the problem

Most pitches lead with the product. A clever model, a sleek interface, a new piece of hardware. The first thing Nicole Junkermann does is set the product to one side and look at the problem behind it. A technology is only as valuable as the difficulty it removes, and the size and shape of that difficulty tells you almost everything about whether the work is worth backing.

The question she returns to is plain. What is genuinely hard here, and for whom. A product that makes an already easy task slightly faster rarely justifies the years of effort a real company demands. A product that makes a genuinely hard task possible, for people who needed it badly, is the kind of thing that can grow roots. This is why her interests across artificial intelligence, healthtech, biotech, fintech and deep technology share a common centre. In each field she is looking for important problems, not impressive demonstrations.

Starting with the problem also keeps the conversation honest. It is easy to be dazzled by what a technology can do and slow to ask whether anyone actually needs it. Nicole Junkermann would rather begin at the other end, with the need, and work back toward the tool.

The team behind the idea

Ideas are cheaper than people think, and teams are more important. A great deal of what Nicole Junkermann assesses comes down to the founders: whether they understand their problem deeply, whether they are honest about what they do not yet know, and whether they have the resilience to keep going when the work gets hard. This is the focus of a companion note on investing in founders, not just ideas.

What she looks for is a particular blend. Conviction strong enough to carry a company through difficult years, paired with the openness to change course when the evidence demands it. Founders who only have conviction can march confidently in the wrong direction. Founders who only have flexibility can drift. The best teams hold both, and they tend to talk about their problem with a clarity that is hard to fake.

Honesty matters as much as brilliance. A team that tells you plainly what is not working yet is far easier to back than one that has an answer for everything. The first kind learns. The second kind is often performing.

Does it work in the real world

There is a wide gap between a technology that works in a controlled setting and one that works in the messy, impatient real world. Nicole Junkermann pays close attention to that gap. A model that performs beautifully on clean data may struggle with the noise of real life. A medical tool that impresses in a study still has to fit into a clinician's day. A financial product has to earn the trust of people who have every reason to be cautious with their money.

So she looks for evidence of contact with reality. Has the team put their product in front of real users. What did those users do, not what did they say. Where did the technology break, and how did the team respond. Real signals are messier than a polished pitch, and far more reliable. This is the same instinct that runs through the tech notes, where the test of any tool is whether it helps a real person on an ordinary day.

Trust as a feature

In the fields Nicole Junkermann cares most about, trust is not a soft extra. It is the product. People will not hand sensitive health information, their savings, or critical decisions to a system they do not trust, no matter how capable it is. So when she assesses a technology, she treats trust as something to be designed and earned, not assumed.

That means asking how a system handles privacy by default, how it explains itself, and how it behaves when it is uncertain. A tool that knows the limits of its own confidence is far more trustworthy than one that always sounds sure. In healthtech and fintech especially, the companies that win over the long run are usually the ones that took trust seriously when it was inconvenient to do so.

Durability over momentum

It is tempting to chase whatever is moving fastest. Momentum feels like proof. But momentum can be borrowed, bought or simply lucky, and it fades. Nicole Junkermann is more interested in durability: the qualities that let a company still matter in five or ten years. A real advantage in science or engineering. A product people come to rely on. A team that compounds its own learning.

This is why patience sits at the centre of her approach, a theme she returns to in a note on why patient capital matters in tech. The most valuable technologies often look quiet in their early years. Backing them well means being willing to wait through the unglamorous middle, when the science is being turned into something dependable and the headlines have moved elsewhere.

A working checklist

None of this reduces to a formula, and Nicole Junkermann would be the first to say so. Judgement is the point. But the questions below capture the spirit of how she reads a new technology before deciding to back it.

• What hard, real problem does this solve, and for whom.
• Does the team understand that problem more deeply than anyone else.
• Is there evidence the product works outside a controlled setting.
• Has trust been designed in, especially around privacy and uncertainty.
• Would this still matter in five years if the early excitement faded.
• Can patient support help the team through the difficult middle years.

Run a technology through these questions and the picture usually becomes clear. The ones worth backing tend to answer them quietly and convincingly. To see how this thinking plays out across her wider map of interests, you can return to the work of Nicole Junkermann or read about her map of innovation from fintech to biotech.

Frequently asked questions